top of page

- 1 min read

The Lancet Journal - Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2

Updated: Feb 5

Published: January 29, 2024 https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00009-9/fulltext

Recent Posts

Vivacelle Bio Commemorates Sepsis Awareness Month, Recognizing the Leading Cause of Death in U.S. Hospitals

Treating Septic Shock with Nanoparticle Formulation that Redistributes Nitric Oxide with Dr. Harven DeShield - Vivacelle Bio on the Empowered Patient Podcast with Karen Jagoda

Vivacelle Bio Enrolls First Patient in Phase 3 Trial of Hypovolemia Due to Septic Shock for Phospholipid Nanoparticle-Based VBI-S

KANSAS CITY, Mo., Sept. 3, 2024 /PRNewswire/ -- Vivacelle Bio , a late-stage biopharma company developing life-saving treatments for...

Commentaires

bottom of page